Product Description
Mechanisms of Action: PDE3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fudan University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome|Acute Lung Injury
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ChiCTR2200055129 | N/A |
Recruiting |
Heart Failure, Acute |
2024-10-12 |
|||
| PETARDS | P4 |
Unknown status |
Acute Lung Injury|Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome |
2023-10-01 |
2024-11-02 |
Primary Endpoints |